Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175786 | 0.89 | SNCA (0.67) | SNCACYP3A4HPGDADRB2ADRB1 | |
| SCHEMBL8850793 | 0.86 | CYP4A11 (0.57) | SNCACYP3A4SMN1; SMN2ALDH1A1TSHR | |
| Benzyl Alcohol SCHEMBL23391584 | 0.86 | LMNA (0.60) | SNCACYP3A4HPGDALDH1A1TSHR | |
| SCHEMBL12228311 | 0.86 | SNCA (0.56) | SNCACYP3A4SMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL10356047 | 0.84 | SNCA (0.55) | SNCACYP3A4HPGDSMN1; SMN2ADRB2 | |
| SCHEMBL18148926 | 0.84 | LOXL2 (0.56) | SNCACYP3A4HPGDALDH1A1TSHR | |
| SCHEMBL513603 | 0.84 | SNCA (0.55) | SNCACYP3A4HPGDADRB2ADRB1 | |
| SCHEMBL10590383 | 0.84 | SNCA (0.55) | SNCACYP3A4HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL461801 | 0.83 | SNCA (0.61) | SNCACYP3A4ADRB2ADRB1ADRB3 | |
| SCHEMBL17386391 | 0.83 | SNCA (0.61) | SNCACYP3A4HPGDADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0813516-B1 | PROCESS FOR THE PREPARATION OF STILBENEDICARBOXYLATE ESTERS | EASTMAN CHEM CO (US) | 1999-12-01 | — | — | EP | claimed |
| EP-0813516-A1 | PROCESS FOR THE PREPARATION OF STILBENEDICARBOXYLATE ESTERS | EASTMAN CHEMICAL COMPANY (US) | 1997-12-29 | — | — | EP | claimed |
| WO-1996027578-A1 | PROCESS FOR THE PREPARATION OF STILBENEDICARBOXYLATE ESTERS | EASTMAN CHEMICAL COMPANY (US) | 1996-09-12 | — | — | WO | claimed |
| US-5473098-A | Process for the preparation of stilbenedicarboxylate esters | EASTMAN CHEMICAL COMPANY (US) | 1995-12-05 | — | — | US | claimed |
| US-6906046-B2 | Pharmaceutical uses and synthesis of benzobicyclooctanes | CELLTECH R & D INC. (US) | 2005-06-14 | — | — | US | disclosed |
| CN-1188401-C | Heterocyclic amide compound and its pharmaceutical use | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2005-02-09 | — | — | CN | disclosed |
| EP-0826671-B1 | HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| CN-1131210-C | Heterocyclic amide compound and medical use thereof | MITSUBISHI SEIYAKU CO LTD (JP) | 2003-12-17 | — | — | CN | disclosed |
| US-20030069305-A1 | Pharmaceutical uses and synthesis of benzobicyclooctanes | CELLTECH R & D, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002051851-A2 | PHARMACEUTICAL USES AND SYNTHESIS OF BENZOBICYCLOOCTANES | CELLTECH R & D, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
| CN-1304931-A | Heterocyclic amide compound and medical use thereof | EFUKU CO LTD (JP) | 2001-07-25 | — | — | CN | disclosed |
| EP-0813516-B1 | PROCESS FOR THE PREPARATION OF STILBENEDICARBOXYLATE ESTERS | EASTMAN CHEM CO (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5597839-A | TREATMENT OF SKIN DISORDERS OR ANTIINFLAMMATORY AGENTS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1997-01-28 | — | — | US | disclosed |
| US-5567721-A | AROMATIC UREA COMPOUND FOR SKIN DISORDER, RHEUMATIC DISEASE, RESPIRATORY DISORDER AND EYE DISORDER | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 1996-10-22 | — | — | US | disclosed |
| WO-1996027578-A1 | PROCESS FOR THE PREPARATION OF STILBENEDICARBOXYLATE ESTERS | EASTMAN CHEMICAL COMPANY (US) | 1996-09-12 | — | — | WO | disclosed |
| WO-1996027578-A1 | PROCESS FOR THE PREPARATION OF STILBENEDICARBOXYLATE ESTERS | EASTMAN CHEMICAL COMPANY (US) | 1996-09-12 | — | — | WO | disclosed |
| US-5473098-A | Process for the preparation of stilbenedicarboxylate esters | EASTMAN CHEMICAL COMPANY (US) | 1995-12-05 | — | — | US | disclosed |
| US-5473098-A | Process for the preparation of stilbenedicarboxylate esters | EASTMAN CHEMICAL COMPANY (US) | 1995-12-05 | — | — | US | disclosed |
| US-5439925-A | Skin disorders, rheumatic diseases | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-08-08 | — | — | US | disclosed |
| US-5387594-A | Administering for topical and systemic treatment of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069305-A1 | Pharmaceutical uses and synthesis of benzobicyclooctanes | CXCL8, CASP8, IL18 | SNCA 1656/4885CYP3A4 159/4885HPGD 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.